Signaturefd, LLC Uro Gen Pharma Ltd. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Signaturefd, LLC holds 380 shares of URGN stock, worth $4,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares

380

Previous 497 23.54%

Holding current value

$4,525

Previous $8,000 50.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$12.7 - $17.92 $1,485 - $2,096	-117 Reduced 23.54%	380 $4,000
Q2 2024 Jul 29, 2024	SELL	$12.72 - $19.2 $1,946 - $2,937	-153 Reduced 23.54%	497 $8,000
Q1 2024 May 03, 2024	BUY	$13.81 - $19.33 $469 - $657	34 Added 5.52%	650 $9,000
Q4 2023 Jan 31, 2024	BUY	$10.87 - $15.93 $5,826 - $8,538	536 Added 670.0%	616 $9,000
Q3 2023 Nov 03, 2023	BUY	$8.84 - $22.64 $707 - $1,811	80 New	80 $1,000
Q4 2021 Jan 25, 2022	SELL	$9.03 - $19.13 $13,626 - $28,867	-1,509 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$14.31 - $18.39 $18,917 - $24,311	1,322 Added 706.95%	1,509 $25,000
Q2 2021 Jul 26, 2021	BUY	$15.2 - $20.94 $896 - $1,235	59 Added 46.09%	187 $3,000
Q1 2021 Apr 30, 2021	SELL	$17.99 - $26.96 $449 - $674	-25 Reduced 16.34%	128 $2,000
Q4 2020 Feb 11, 2021	SELL	$17.54 - $25.43 $228 - $330	-13 Reduced 7.83%	153 $3,000
Q3 2020 Nov 03, 2020	BUY	$18.81 - $26.42 $2,238 - $3,143	119 Added 253.19%	166 $3,000
Q2 2020 Jul 30, 2020	SELL	$16.5 - $29.7 $1,336 - $2,405	-81 Reduced 63.28%	47 $1,000
Q1 2020 Apr 23, 2020	SELL	$13.68 - $34.6 $39,288 - $99,371	-2,872 Reduced 95.73%	128 $2,000
Q3 2019 Oct 16, 2019	BUY	$23.83 - $36.44 $71,490 - $109,320	3,000 New	3,000 $71,000

Others Institutions Holding URGN

# of Institutions

130

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $271M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account